Related Experiment Video
Updated: Jan 6, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
Atrial Arrhythmias in Cardiac Sarcoidosis-Case Presentation and Systematic Review
Emily C Hodkinson1, Luis Quininir2, Edward Hsiao3
1Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.
Insights
Atrial arrhythmias (AA) are a frequent and under-recognized complication of cardiac sarcoidosis (CS), affecting up to 40% of patients. Early recognition and tailored management strategies are crucial for improving patient outcomes in this rare disease.
Area of Science:
- Cardiology
- Immunology
- Pulmonology
Background:
- Cardiac sarcoidosis (CS) is a rare multisystem disease affecting approximately 5% of sarcoidosis patients.
- Current CS diagnosis and management primarily target left ventricular dysfunction, ventricular arrhythmias, and AV conduction disease.
- Atrial arrhythmias (AA) are an under-recognized manifestation of CS.
Purpose of the Study:
- To systematically review the literature on the prevalence and management of AA in CS.
- To highlight AA as a potentially predominant cardiac manifestation in CS.
- To inform future diagnostic criteria for CS.
Main Methods:
- Systematic literature review.
- Emphasis on prevalence and management of AA in CS.
- Discussion of diagnostic modalities like Positron Emission Tomography (PET).
Main Results:
- AA occur in up to 40% of CS patients.
- AA can result from direct granulomatous infiltration or secondary atrial myopathy.
- AA are associated with increased hospitalizations and reduced quality of life.
- AA may be the primary cardiac presentation in CS.
Conclusions:
- AA are a frequent and significant manifestation of CS.
- Current treatments (immunosuppression, anti-arrhythmics, ablation) have high recurrence rates in CS.
- Further multi-center studies are needed to guide AA management in CS.
Abstract:
Sarcoidosis is a rare idiopathic, multiorgan disease with clinical cardiac involvement in approximately 5% of cases. Diagnosis and management of cardiac sarcoidosis (CS) have mainly focused on impaired LV function, ventricular arrhythmias, and atrio-ventricular conduction disease. Atrial arrhythmias (AA) may be an under-recognized manifestation of sarcoidosis, and the purpose of the study was to perform a systematic review of the current literature, with an emphasis on the prevalence and management of AA in CS. AA occur as a result of direct infiltration of granulomatous disease in the atria or secondary to atrial myopathic changes from pulmonary or ventricular disease. Positron emission tomography (PET) is the modality of choice for surveillance of disease activity in the atria. AA occur frequently, in up to 40% in patients with CS, and may be associated with frequent hospitalization and reduction in quality of life. Moreover, AA may be the predominant cardiac manifestation, and there should be some consideration to include AA as part of future iterations of the diagnostic criteria for CS. Contemporary treatment involves a combination of immunosuppression, anti-arrhythmic therapy, and catheter ablation, but recurrence occurs more frequently than in patients with non-CS AA. Further systematic studies, likely in the form of multi-center observational cohort studies, are required to inform guidelines on the specific management of AA in CS.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy III: Hypertrophic Cardiomyopathy

